🇺🇸 FDA
Patent

US 12162937

Methods of treating an inflammatory disorder by administering an antibody which binds to a connexin CX43 hemichannel

granted A61KA61K49/0008A61P

Quick answer

US patent 12162937 (Methods of treating an inflammatory disorder by administering an antibody which binds to a connexin CX43 hemichannel) held by The Board of Regents of the University of Texas System expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K49/0008, A61P, A61P19/02